Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure.The Sixth Report of the Joint National Committee (JNC-VI) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med1997; 157:2413-46.
2.
Collins C., Peto R., MacMahon S. et al. Blood pressure, stroke and coronary heart disease. Part II. Short-term reductions in blood pressure overview of randomized drug trials in their epidemiological context. Lancet1990 ; 335:827-38.
3.
Thijs L., Fagard R., Lijuen F., Staessen J.,Van Hoof R.,Amery A.A meta-analysis of outcome trials in elderly hypertensives. J Hypertens1992; 10:1103-09.
4.
WHO-ISH Hypertension Guidelines Committee.1999World Health Organization - In ternational Society of Hypertension Guidelines for the Management of Hypertension . J Hypertens1999;17:151-85.
5.
McKee PA , Castelli WP, McNamara OM, Kannel WBThe natural history of congestive heart failure. The Framingham Heart Study. N Engl J Med1971 ; 285:1441-6.
6.
Vasan RS, Levy D.The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Arch Intern Med1996 ; 156:1789-96.
7.
Vasan RS, Benjamin EJ, Levy D.Prevalence, clinical features and prognosis of diastolic heart failure:An epidemiologic perspective.JAm Coll Cardiol1995; 26:156.
8.
Frohlich EDCurrent clinical pathophysiologic considerations in essential hypertension . Med Clin North Am, 1997;81:1113-29.
9.
Frohlich EDRisk mechanisms in hypertensive heart disease. Hypertension1999; 34:782-9.
10.
Frohlich EDIn Hypertension: Evaluation and Treatment. (Chapter 7). Williams &Wilkins: Baltimore1998; 119-40.
11.
Nixenberg A. ,Antony I.Epicardial coronary arteries are not adequately sized in hypertensive patients. J Am Coll Cardiol1996; 27:1115-23.
12.
Weber KT, SunY., Guarda E.Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension1994; 23:869-77.
13.
Weber KTExtracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation1997 ; 96:4065-82.
14.
Marcus ML, Duty DB, Hiratska LF,Wright CB, Eustham CLDecreased coronary reserve:A mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. N Engl J Med1982; 307:1362-7.
15.
Opherk D., Nall G., Zebe H. et al. Reduction of coronary reserve:A mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation1984; 69:1-7.
16.
Brash JE, Jr, Cannon RO, Schenke WH et al. Angina due to coronary microvascular disease in hypertension without left ventricular hypertrophy. N Engl J Med1988; 319:1302-07.
17.
Houghton JL , Frank MJ, Carr AA, von Dohlen TW, Prisant LMRelations among impaired coronary flow reserve: left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without destructive coronary artery disease. J Am Coll Cardiol1990;15:43-51.
18.
Scheler S., Wolfgang M., Strauer BEMechanisms of angina pectoris with essential hypertension and normal epicardial arteries by arteriogram. Am JCardiol1994 ; 73:478-82.
19.
Treasure CB , Klein JL, Vita JA et al. Hypertenion and left ventricular hypertrophy are associated with impaired endothelium-mediated relazation in human coronary resistance vessels. Circulation1993;87:86-93.
20.
Lüscher TFThe endothelium in hypertension: bystander, target or mediator?J Hypertension1994; 12: 105-16.
21.
Küng CF , Lüscher TFDifferent mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension1995; 25:194-200.
22.
Gauthier-Rein KM, Rusch NJDistinct endothelial impairment in coronary microvessels from hypertensive Dahl rats. Hypertension1998; 31:328-34.
23.
Zeiher AM, Drexler H., Saurbier B., Just H.: Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest1993; 92:652-62.
24.
Drexler H., Zeiher AM, Meinzer K., Just H.Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet1991; 338: 1546-50.
25.
Bøttchen M. , Bøtker HE, Sonne H., Nielsen TT, Czernin J.Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with Syndrome X. Circulation1999; 99:1795-801.
26.
Frohlich ED ,Apstein C., Chobanian AV et al. The heart in hypertension. N Engl J Med1992; 327:998-1008.
27.
Kannel WB, Dawber TR, Kagan A., Revorskie N., Sacks J.Factors of risk in the development of coronary heart disease - six year follow up experience. The Framingham Study. Ann Intern Med1961; 55:33-56.
28.
Kannel WB, Gordon T., Offut D.Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham Study. Ann Intern Med1969; 71:99-105.
29.
Frohlich EDIs reversal of left ventricular hypertrophy in hypertension beneficial? Hypertension1991 ; 18(I):133-38.
30.
Frohlich EDThe First Irvine H. Page Lecture:The mosaic of hypertension: Past, present, and future. J Hypertens1988; 6:S2-11 .
31.
Kozakova M. , Polumbo C., Parati L., Pittella G., Galetta F., L'Abbate A.Mechanisms of coronary flow reserve impairment in human hypertension: An integrated approach by transthoracic and trans-esophageal echocardiography. Hypertension1997; 29:551-9.
32.
Sakoshima J. , Izumo S.The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol1997; 59:551-71.
33.
Swynghedauw B.Molecular mechanisms of myocardial remodeling . Physiol Rev1999; 79:216-62.
34.
Nishiyama K. , Nishiyama A., Frohlich EDRegional blood flow in normotensive and spontaneously hypertensive rats.Am J Phyiol1976; 230:691-8.
35.
Tsuchiya M. , Ferrone RA, Walsh GM, Frohlich EDRegional blood flows measured in conscious rats by the combined Fick and microsphere methods . Am J Physiol1978; 235:H357-360.
36.
Ishise S., Pegram BL, Yamamoto J., Kitamura Y., Frohlich EDReference sample microsphere method: Cardiac output and blood flows in conscious rats. Am J Physiol1980; 239:H443-449.
37.
Soria F., Frohlich ED,Aristizabal D. et al. Preserved cardiac performance with reduced left ventricular mass in conscious exercising spontaneously hypertensive rats. J Hypertens1994; 12:585-9.
38.
Nunez E., Hosoya K., Susic D., Frohlich EDEnalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension1997; 29:519-24.
39.
Susic D., Nunez, Hosoya H, Frohlich EDCoronary hemodynamics in aging spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. J Hypertens1998; 16:231-7.
40.
Rossi MAPathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens1998;16:1031-41.
41.
Folkow B.The Fourth Vollrad Lecture: Cardiovascular structural adaptation: Its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med1975; 48:205s-14s.
42.
Susic D., Frohlich EDPharmacologic agents on cardiovascular mass and coronary hemodynamics in aging spontaneously hypertensive rats. J Hypertens1999; 17:1-7.
43.
Varagic J., Susic D., Frohlich EDAT2 receptors contribute to hypotension and antifibrosis but not coronary hemodynamic improvement or reduced LV mass, by AT1 receptor inhibition. Hypertension (in press).
44.
Schwartzkopff B., Brehm M., Mundhenke M., Strauer BERepair of coronary arterioles after treatment with perindopril in hypertensive heart disease . Hypertension2000; 36:220-5.
45.
Brilla CG, Funck RC, Rupp H.Lisinopril-mediated regression of myocardial fibrosis in patieints with hypertensive heart disease. Circulation2000; 102(12): 1388-99.
46.
Arita M., Horinaka S., Frohlich EDBiochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens1993;11:951-9.
47.
Arita M., Horinaka S., Komatsu K., Frohlich EDReversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes. J Hypertens1993; 11:S354-S355.
48.
Aristizabal D., Messerli FH, Frohlich EDDisparate structural effects of left and right ventricles by angiotensin converting enzyme inhibitors and calcium antagonists . Am J Cardiol1994 ; 73:483-7.
49.
Susic D., Francischetti A., Frohlich EDProlonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension1999; 33:451-5.
50.
Susic D.,Varagic J.,Frohlich EDL-arginine with angiotensin-converting enzyme inhibition improves cardiac function and coronary dynamics in two year old Wistar Kyoto rats. Hypertension (in press)
51.
US Renal Data Systems.1995Annual Data Report. National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, III: incidence and causes of treated ESRD. Am J Kidney Dis 1995;26:S39-S50.
52.
Hostetter TH , Olson JL, Rennke HG, Venkatachalam MA, Brenner BMHyperfiltration in remnant nephros: a potentially adverse response to renal ablation. Am J Physiol1981:241:F85-F93.
53.
Brenner BM, Meyer TW, Hostetter THDietary protein intake and the progressive nature of kidney disease: the tale of hemodynamically mediated glomerular disease in the pathogenesis of progressive glomerular schlosis in aging, renal ablation, and intrinsic renal disease . N Engl J Med1982; 3007:652-9.
54.
Anderson PW , Doy S., Hsueh WAAngiotensin II causes mesangial cell hypertrophy . Hypertension1993; 21:166-72.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropath. The Collaborative Study Group. N Engl J Med1993; 320:1456-62.
57.
Ukpds Group .Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. BMJ1998; 317:713-20.
58.
Hansson L., Lindholm LH, Niskanen L. et al. Effects of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet1999; 353(9153):611-6.
59.
Sowers JR, Epstein M., Frohlich EDDiabetes, hypertension and cardiovascular disease:An update. Hypertension (in press) 60. UKPDS Group. UK Prospective Diabetes Study 38: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ1998; 317:703-13.
60.
Frohlich EDArthur C.Corcoran Memorial Lecture: Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension1997; 29(part 2):188-93.
61.
Ono H., Ono Y., Frohlich ED: Nitric oxide synthase inhibition in spontaneously hypertensive rats . Hypertension1995;26: 249-55.
62.
Komatsu K., Frohlich ED, Ono H., Ono Y., Numabe A., Willis GWGlomerular dynamics and morphology of aged SHR. Hypertension1995; 25:207-13.
Uchino K., Nishikimi T., Frohlich EDAlpha-1 adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistance in SHR. Am J Physiol1991; 261:R576-R580.
65.
Ono H., Ono Y., Frohlich EDACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneusly hypertensive rats. Hypertension1996;27:176-83.
66.
Ono Y., Ono H., Frohlich EDHydrochlorothiazide exacerbates nitric oxide blockades nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens1996; 14:823-8.
67.
FrancischettiA,Ono H., Frhlich EDRenoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension1998; 31:795-801.
68.
Nakamura Y. , Ono H., Zhou X., Frohlich EDAngiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in L-NAME/SHR rats. Hypertension (in press).
69.
Ono H., Ono Y., Frohlich EDL-Arginine reverses severe nephrosclerosis in aged spontaneously hypertensive rats. J Hypertens1999; 17:121-8.
70.
Nakamura Y. , Ono H., Frohlich EDDifferential effect of T-and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension1999; 34:273-8.
